Cardiologists to highlight capabilities of InfraReDx LipiScan Coronary Imaging Program in ACC.

Muller, M.D., founder and chief executive officer of InfraReDx Tuesday, March 16 9:30 a.m.m. Gurbel, M.D.m., InfraReDx Booth # 254 ‘Developments in Intra-coronary Imaging in the Past Year – NIR, IVUS, OCT and Others’ Professional: James E. Muller, M.D., founder and ceo of InfraReDx.. Cardiologists to highlight capabilities of InfraReDx’ LipiScan Coronary Imaging Program in ACC.10 and i2 Summit InfraReDx, Inc. The meeting, named ACC. InfraReDx’s LipiScan near-infrared spectroscopy catheter is the only FDA-cleared item to detect and measure the intracoronary composition of lipid primary plaque, which cannot be detected by generally used diagnostic tests such as for example treadmill exams and coronary angiograms. Lipid core-comprising plaque is thought to be ‘vulnerable plaque’ that can rupture and form harmful blood clots resulting in coronary thrombosis.However, near half of these tumors develop level of resistance to endocrine therapy, stated Tekmal. In this preclinical study, researchers treated estrogen receptor-positive tumors currently resistant to letrozole with letrozole and fidarestat. As an inhibitor of aldose reductase enzyme, fidarestat blocks the fat burning capacity of glucose in tumor cells. Together, the combination effectively re-sensitized the cells to letrozole, allowing for effective endocrine therapy and even more cell death. Researchers believe increased glucose metabolism plays a part in oxidative stress, which, in turn, could alter intracellular signalling by influencing the regulation of proteins kinases that are known to be involved in therapy resistance.